Jump to start of content

Technical Support for those taking the Knowledge Check-In at home/in office Expand/Collapse the ABIM alert.

Technical assistance on the day of your Knowledge Check-In assessment is available by chatting with a Pearson VUE agent. We are here to help! You may also call 800-606-0259 to reach an ABIM Customer Relationship Advocate, in the event you are unable to connect to a Pearson VUE agent.

ABIM Scheduled Maintenance… Expand/Collapse the ABIM alert.

ABIM.org will be going through scheduled maintenance from 6 p.m. ET, Sat., 4/24/21 to 6 a.m. ET, Sun., 4/25/21. During this time, the ABIM Physician Portal will be unavailable. We apologize for any inconvenience this may cause. Thank you for your patience.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Medical Oncology Board Exam Committee

Expand All | Collapse All

Pamela N. Munster, MD, Chair

Pamela N. Munster, MDDr. Munster, who is board certified in Internal Medicine and Medical Oncology, is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center.

She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.

Her basic laboratory research interests are in the area of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.

Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research. She serves as Chair of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Dr. Munster received her medical degree from the University of Bern, Switzerland, completed her residency in internal medicine at Indiana University Medical Center then moved to Memorial Sloan Kettering Cancer Center, New York, for her oncology and hematology fellowship.

As of April 2019, Dr. Munster reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of California, San Francisco, from the following companies:

  • Amgen
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • Celgene
  • Cleave Biosciences
  • Clovis Oncology
  • Corcept Therapeutics
  • Genentech
  • GlaxoSmithKline
  • Medivation
  • Medimmune
  • Merck & Co.
  • Nektar Therapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Roche
  • Sanofi Pasteur

Attendance at investigators’ meetings, with compensation for travel expenses from the following companies:

  • Merck
  • Merrimack
  • Xynomics

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Beigene

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Epigene
  • Xynomics

Work as an author for following companies, with compensation:

  • Celgene
  • Corcept
  • Pharmacyclics
  • Tesaro

Dr. Munster holds a healthcare-related patent from Alessa Therapeutics, with no income to date. She also serves on the Board of Directors of Alessa Therapeutics.

Dr. Munster serves on advisory boards for the American Society of Clinical Oncology, the National Cancer Institute and the National Institutes of Health.

Dr. Munster also reported receiving educational grants from the National Cancer Institute, the National Institutes of Health, and the University of California-San Francisco to support fellows.

Deborah K. Armstrong, MD

Deborah K. Armstrong, MDDr. Armstrong is Professor of Oncology and of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. She is board certified in Internal Medicine and Medical Oncology.

Previously, Dr. Armstrong chaired the Oncology Drugs Advisory Committee for the U.S. Food & Drug Administration. She was a Principal Investigator for the Gynecologic Oncology Group (now NRG Oncology), serving on Ovarian Cancer, Medical Oncology and Phase I committees. In addition, she has participated as a scientific reviewer for National Cancer Institute (NCI), Department of Defense, National Comprehensive Cancer Network and for the Stand Up to Cancer Ovarian Cancer Dream Team award, among others. She is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Dr. Armstrong is a member of the Board of Directors of the Society of Gynecologic Oncology. and co-chairs the Ovarian Cancer Task Force for the NCI. She is a representative of Johns Hopkins to the National Cooperative Cancer Network serving as co-Chair of the ovarian cancer panel. Dr. Armstrong directs the gynecologic oncology clinical trials program at the Johns Hopkins Kimmel Cancer Center and the breast and ovarian cancer genetic counseling service that identifies patients at risk for cancer and recommends strategies for cancer screening and prevention.

She was awarded a Komen Foundation Fellowship, a Young Investigator Award from American Society of Clinical Oncology, a Career Development Award from the American Cancer Society, the Ladies Home Journal Breakthrough Achievement Award, the Rosalind Franklin Award for Excellence in Ovarian Cancer Research and the Johns Hopkins Department of Medicine Osler Housestaff Teaching Award.

Dr. Armstrong received a bachelor's degree in bacteriology from the University of California at Berkeley then attended the George Washington University School of Medicine and was elected to Alpha Omega Alpha. Dr. Armstrong trained in internal medicine at the University of Pittsburgh and served as Chief Medical Resident before completing medical oncology fellowship at the Johns Hopkins Oncology Center.

As of January 2020, Dr. Armstrong reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Johns Hopkins University, from the following companies:

  • AstraZeneca, for two ovarian cancer trials.
  • Clovis Oncology, for two ovarian cancer trials.
  • Eisai, for an ovarian cancer trial.
  • Pfizer, for an ovarian cancer trial.
  • Syndax, for an ovarian cancer trial.
  • Tesaro, for an ovarian cancer trial.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • AbbVie, Member
  • AstraZeneca, Chair

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Cue Biopharma, to provide guidance regarding development of immune targeted therapy for cervical cancer, receiving compensation for travel and honoraria.
  • Morphotek, to provide guidance regarding the drug farletuzumab in treating ovarian cancer, receiving honoraria.

Work as an author or editor for the following company, with compensation as listed below:

  • UpToDate, receiving compensation as an editor for ovarian cancer topics.

Dr. Armstrong serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • National Comprehensive Cancer Network, Chair of Ovarian Cancer Committee, Chair of YIA award recipient Selection Committee, receiving honoraria.

Bartosz Chmielowski, MD., Ph.D

Dr. Chmielowski is an Associate Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles.

He has been ABIM certified in Medical Oncology and Hematology since 2008. Dr. Chmielowski has been a UCLA faculty member since 2008, and his both clinical and laboratory research concentrates on the development of new therapies for patients with melanoma, non-melanoma skin cancers and sarcoma. He has a special interest in the development of new immunotherapeutic agents and new combination immunotherapies not only in melanoma, but also in non-melanoma skin cancers and sarcoma including patients with gastrointestinal stromal tumors. In addition, he studies new molecularly targeted agents in both sarcoma and melanoma.

He graduated from the Medical School at Wroclaw, Poland. He moved to the United States to pursue research career in immunology at the Medical College of Georgia in Augusta, GA. He concentrated on studying T cell development in the thymus, especially the processes of positive and negative selection. His research resulted in a doctoral thesis.

He completed his residency in Internal Medicine at the Medical College of Georgia in Augusta, GA, and next, did his fellowship in Hematology-Oncology at UCLA.

As of March 2020, Dr. Chmielowski reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of California Los Angeles, from the following companies:

  • Eli Lilly & Company
  • Incyte
  • Bristol-Myers Squibb
  • Macrogenics
  • Array Biopharma
  • EMD Serono
  • Daiichi Sankyo
  • Merck
  • Karyopharm
  • Infinity Pharma
  • Rgenix
  • Biothera
  • Aeglea
  • Advenchen
  • Idera
  • Neon
  • Xencor
  • Compugen
  • Iovance
  • PACT Pharma
  • RAPT Therapeutics

Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Deciphera
  • Ideaya
  • Epizyme

Teaching in satellite symposia funded by the following companies, with compensation for travel expenses and honoraria:

  • Sanofi Genzyme

Work as an author or editor for following companies, with compensation as listed:

  • Wolters Kluwer, receiving compensation as editor of the Manual of Clinical Oncology.

Olatoyosi M. Odenike, MD

Olatoyosi M. Odenike, MDDr. Odenike, a board certified medical oncologist, is an Associate Professor of Medicine at the University of Chicago. Dr. Odenike's clinical research and medical practice is focused on myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes and chronic myeloproliferative neoplasms. She has a particular interest in new drug development in these diseases.

Prior to joining the faculty at the University of Chicago, Dr. Odenike worked as an Attending Physician at Roseland Community hospital, a medically underserved community on the South Side of Chicago.

Dr. Odenike currently serves as member of the American Board of Internal Medicine Medical Oncology Board Exam Committee and Medical Oncology Specialty Board. She is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. Dr. Odenike is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. Additionally, she has served on various professional committees including American Society of Clinical Oncology (ASCO) Scientific Program Committee for which she also served as a Track Leader, ASCO Cancer Communications Committee and the Best of ASCO Program Committee, and she has served as Chair of Educational Programs for both ASCO and the American Society of Hematology(ASH)and is a member of the ASH Consult a Colleague Program.

She has served in various editorial capacities and review committees including the Conquer Cancer Foundation of ASCO grant review committee, ASCO International Innovation Grant review subcommittee and currently serves as a member of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike serves on the Molecular and Cellular Hematology National Institutes of Health Study Section. She is the recipient of an ASCO Career Development Award and was listed in Best Doctors in America as well as Castle Connolly's Top Doctors.

Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University of Illinois and her fellowship training in hematology/oncology at the University of Chicago.

As of May 2019, Dr. Odenike reported the following external relationships:

Funding for clinical trial expenses, salary support staff, paid to the University of Chicago, from the following companies:

  • AbbVie
  • Agios
  • Astex
  • Celgene
  • CTI Biopharma
  • Janssen
  • Incyte
  • Millennium
  • Oncotherapy Sciences
  • Plexxicon

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • AbbVie, for serving on an advisory board regarding the role of venetoclax in adult acute myeloid leukemia, receiving honoraria.
  • Celgene, for serving on advisory boards on JAK inhibitors in myelofibrosis and luspatercept in myelodysplastic syndrome, receiving reimbursement for travel expenses and honoraria.

Dr. Odenike serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Alliance Cooperative Group, Leukemia Core Committee Member, without compensation.
  • American Society of Clinical Oncology, International Innovation Grant Review Subcommittee Member
  • National Institutes for Health, Molecular and Cellular Hematology Standing Committee member, receiving reimbursement for travel expenses and honoraria.
  • American Society of Hematology: Education Program, receiving honoraria.
  • The France foundation: Educational Symposium on adult acute myeloid leukemia and myelodysplastic syndrome matters, receiving reimbursement for travel expenses and honoraria.

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MDDr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine in Atlanta, Georgia. He is also the Roberto C. Goizueta Chair for Cancer Research and the Deputy Director of the Winship Cancer Institute of Emory University. He is board certified in both Internal Medicine and Medical Oncology.

Before joining Emory in 2007, Dr. Ramalingam served as an Assistant Professor of Medicine at the University of Pittsburgh.

Dr. Ramalingam is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. He serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee and he serves on the editorial boards of leading cancer journals. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12).

His research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. As an author, he has published more than 200 original manuscripts, review articles, editorials and book chapters.

Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, Michigan, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, Pennyslvania.

As of July 2019, Dr. Ramalingam reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Emory University, from the following companies:

  • Amgen, for a Phase 1 study of an anti-c-fms monoclonal antibody.
  • AstraZeneca, for a study of an EGFR inhibitor in non-small cell lung cancer.
  • Bristol-Myers Squibb, for a Phase 2 clinical trial of immunotherapy in advanced non-small cell lung cancer.
  • Genmab, for a Phase 1 clinical trial of an Anti-AXL ADC.
  • Merck, for a Phase 2 clinical trial of immunotherapy in non-small cell lung cancer.
  • Tesaro, for a Phase 2 clinical trial of TSR 042 in combination with niraparib.
  • Takeda, for a Phase 2 clinical trial of an oral agent’s antitumor activity.

Service on a research-related expert panel or advisory board, receiving reimbursement for travel expenses and honoraria from the following companies:

  • AstraZeneca, for a scientific advisory board to provide input on the development of EGFR inhibitors in lung cancer, receiving reimbursement for travel expenses and honoraria.
  • Bristol-Myers Squibb, for a scientific advisory board meeting to provide input on development of immunotherapy for lung cancer, receiving honoraria.
  • Ariad, for a scientific advisory board meeting to provide input on the development of an ALK inhibitor for lung cancer, receiving honoraria.
  • Merck, for a scientific advisory board meeting to provide input on development of immunotherapy for lung cancer, receiving reimbursement for travel expenses and honoraria.
  • Genentech, for a scientific advisory board meeting to provide input on development of novel anticancer agents for lung cancer, receiving reimbursement for travel expenses and honoraria.
  • Tesaro, for a scientific advisory board, receiving honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, receiving honoraria:

  • Eli Lilly & Company, advising on development of novel anticancer agents for lung cancer.

Industry-supported continuing medical education supported by the following, with reimbursement for travel expenses and honoraria:

  • PRIME, continuing medical education symposium speaker receiving reimbursement for travel expenses and honoraria.
  • Medscape, continuing medical education online programs, receiving honoraria.
  • Rockpointe, CME lecture on immunotherapy, receiving honoraria.
  • Research to Practice, CME lecture on lung cancer, receiving reimbursement for travel expenses and honoraria.
  • Physicians Education Resource, continuing medical education symposium speaker, receiving reimbursement for travel expenses and honoraria.

Dr. Ramalingam serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Emory Healthcare, Board of Directors, without compensation.
  • International Association for Study of Lung Cancer (IASLC), Board of Directors, without compensation.
  • Georgia Society of Oncology, President, receiving reimbursement for travel expenses.

Manish A. Shah, MD

Dr. Shah, the Bartlett Family Associate Professor of Gastrointestinal Oncology, is recognized as an excellent clinical and translational investigator focusing on drug development and advancing the care of gastrointestinal malignancies. Presently, his academic titles include Chief, Solid Tumor Oncology Service; Director, Gastrointestinal Oncology Program at Weill Cornell Medicine and Co-Director, Center for Advanced Digestive Care, New York Presbyterian Hospital.

He has published over 100 peer-reviewed articles and has received numerous peer-reviewed funding awards. His research focuses on drug development and understanding mechanisms of resistance to therapy in Gastrointestinal Malignancies.

He received a bachelor of educational studies degree in biomedical engineering from Johns Hopkins University; and his Mdmedical degree from the Harvard/MIT Health Sciences and Training program. His residency was completed in Internal Medicine at Duke Medical Center in Durham, NC, and he completed his training in Oncology at Memorial Sloan Kettering / Weill Cornell Medicine, where he was Chief Fellow.

As of August 2018, Dr. Shah reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Weill Cornell Medicine from the following companies:

  • Boston Biomedical, for a study on colorectal cancer, receiving funding for clinical trial expenses and staff.
  • Merck, for three cancer studies, receiving funding for clinical trial expenses, salary support and staff.
  • Oncolys Biopharma, for a study of IIT study of novel oncolytic adenovirus + pembrolizumab, receiving funding for clinical trial expenses, salary support and staff.

Service on data and safety monitoring boards for the following company, with compensation for travel expenses and honoraria:

  • Boston Biomedical, for a study on pancreatic cancer.

David Vaughn, MD

David Vaughn, MDDr. Vaughn, board certified in Internal Medicine and Medical Oncology, is the Genitourinary Medical Oncology Professor at the Abramson Cancer Center of the University of Pennsylvania. He is also Associate Chief for Clinical Affairs in the Hematology/Oncology Division.

He is a medical oncologist with expertise in the management of patients with bladder, prostate and testicular cancers. Dr. Vaughn's clinical research is focused on development of new treatments for patient with genitourinary cancer as well as the late effects of treatment in long-term survivors of testicular cancer. He is the former Chair of the American Board of Internal Medicine Medical Oncology Self-Assessment Committee and now serves as a member of the ABIM Medical Oncology Board Exam Committee.

Dr. Vaughn received his medical degree from Harvard Medical School (1987), completed his internship (1988) and residency training (1990) at New York Hospital Cornell Medical Center and fellowship training at the Hospital of the University of Pennsylvania (1993).

As of March 2020, Dr. Vaughn reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following companies:

  • Astellas, for a trial of ASP1650 in germ cell tumors.
  • Merck, for a trial of pembrolizumab in bladder cancer.
  • Roche, for a trial of atezolizumab in bladder cancer.

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation for authorship on section on testicular cancer survivors.

Lori J. Wirth, MD

Lori J. Wirth, MDDr. Wirth is the Medical Director of the Head and Neck Oncology Program at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Before joining Mass General in 2008, Dr. Wirth was on staff at the Dana-Farber Cancer Institute. She is board certified in Medical Oncology.

Dr. Wirth is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She currently serves as the Chairperson of the International Thyroid Oncology Program and sits on the National Comprehensive Cancer Network's Thyroid Carcinoma Guidelines Panel. She is also a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee. She has previously served on the Dana-Farber/Harvard Cancer Center Institutional Review Board and the National Cancer Institute's Head and Neck Cancer Steering Committee Recurrent/Metastatic Disease Task Force, and has recently served on the American Joint Committee on Cancer's Endocrine Expert Panel.

Dr. Wirth received her bachelor's degree from Brown University and medical degree from Columbia University's College of Physicians and Surgeons. She completed her internal medicine residency at New York Presbyterian Medical Center-Columbia Presbyterian, and completed a three-year fellowship in the Dana-Farber/Partners CancerCare Hematology/Oncology Program.

As of August 2019, Dr. Wirth reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Massachusetts General Hospital, from the following companies:

  • AstraZeneca, for a study of selumetinib in thyroid cancer and for a study of 5-azacytadine, durvalumab, tremilimumab for recurrent squamous cell carcinoma of the head and neck, receiving funding for clinical trial expenses and staff.
  • Bayer, for an observational study of thyroid cancer, receiving funding for clinical research staff.
  • Eisai, for a study of lenvatinib in thyroid cancer and in a combination Phase I trial, receiving funding for clinical trial expenses and staff.
  • Merck, for a Phase Ib trial with pembrolizumab, receiving funding for clinical trial expenses and staff.
  • LOXO, receiving funding for clinical trial expenses and staff.
  • Tessa Therapeutics, receiving funding for clinical trial expenses and staff.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation for travel expenses and/or honoraria:

  • Eisai, for serving on an advisory board for lenvatinib in thyroid cancer, receiving reimbursement for travel expenses and honoraria.
  • Merck, for serving on an advisory board for pembrolizumab in head and neck cancer, receiving reimbursement for travel expenses and honoraria.
  • Genentech, for consulting on thyroid cancer, receiving honoraria.
  • Ayala, receiving honoraria.
  • Cue, receiving honoraria.
  • Iovance, receiving honoraria.

Dr. Wirth serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, Education Committee Member, receiving reimbursement for travel expenses.
  • International Thyroid Oncology Group, Board Member, receiving reimbursement for travel expenses.